ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interleukins (IL)"

  • Abstract Number: L13 • 2019 ACR/ARP Annual Meeting

    Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Philip J. Mease1, Proton Rahman 2, Alice B. Gottlieb 3, Elizabeth Hsia 4, Alexa Kollmeier 5, Xie Xu 6, Ramanand Subramanian 5, Prasheen Agarwal 5, Shihong Sheng 5, Bei Zhou 5, Désirée van der Heijde 7 and Iain McInnes 8, 1Swedish Medical Center and University of Washington, Seattle, Washington, 2Memorial University of Newfoundland, Newfoundland, Canada, 3Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, 4Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, 5Janssen Research & Development, LLC, Spring House, Pennsylvania, 6Janssen Research & Development, LLC, Spring House, 7Leiden University Medical Center, Leiden, Netherlands, 8Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
  • Abstract Number: L21 • 2019 ACR/ARP Annual Meeting

    Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study

    Atul Deodhar1, Ricardo Blanco 2, Eva Dokoupilova 3, Marleen van de Sande 4, Stephen Hall 5, Anna Wiksten 6, Brian Porter 7, Hanno Richards 6, Sibylle Haemmerle 6 and Jürgen Braun 8, 1Oregon Health & Science University, Portland, OR, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Brno, Czech Republic, 4Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam UMC /University of Amsterdam, Amsterdam, Netherlands, 5Monash University, Melbourne, Australia, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

    Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…
  • Abstract Number: 950 • 2019 ACR/ARP Annual Meeting

    Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease

    Xiao-qing Liu1, Xiaojie Liu 2, Nalin Lai 3, Ting Cheng 1, Chong Gao 4 and Xiao-feng Li 1, 1The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), 2Taiyuan University of Technology, Taiyuan, China (People's Republic), 3Shanxi Medical University, Taiyuan, China (People's Republic), 4Brigham and Women’s Hospital, Harvard Medical School, Boston

    Background/Purpose: Behcet’s disease (BD) is a chronic multisystemic disease characterized by muco-cutaneous and ocular manifestations, with central nervous system, vascular and/or gastro-intestinal involvement. Several studies…
  • Abstract Number: 2881 • 2019 ACR/ARP Annual Meeting

    Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study

    Philip Mease1, Laure Gossec 2, Laura Coates 3, Alice B. Gottlieb 4, Deepak Assudani 5, Barbara Ink 5, Jason Coarse 6, Oscar Irvin-Sellers 5 and Dafna Gladman 7, 1Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 2Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 3University of Oxford, Oxford, United Kingdom, 4Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Philadelphia, PA, 5UCB Pharma, Slough, UK, Slough, United Kingdom, 6UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 7Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada

    Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of…
  • Abstract Number: 1504 • 2019 ACR/ARP Annual Meeting

    Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years

    Helena Marzo-Ortega1, Corinne Miceli-Richard 2, Sonja Gill 3, Marina Magrey 4, Paula Machado 5, Abhijit Shete 6, Jianyuan Wang 6, Susanne Rohrer 6 and Atul Deodhar 7, 1NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, 2Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 3412 – 3075 Hospital Gate, Oakville, Canada, 4Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Novartis Pharma AG, Basel, Switzerland, 7Oregon Health & Science University, Portland, OR

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60%…
  • Abstract Number: 2909 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

    Spencer I Danto1, Negin Shojaee 1, Ravi Shankar P Singh 1, Zorayr Manukyan 2, Jessica Mancuso 1, Elena Peeva 1, Michael Vincent 1 and Jean Beebe 1, 1Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, Cambridge, MA, 2Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, ..

    Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of rheumatoid arthritis (RA). Toll-like receptor (TLR) stimulation activates the innate immune system,…
  • Abstract Number: 1517 • 2019 ACR/ARP Annual Meeting

    Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis

    Iain McInnes1, Dafna Gladman 2, Atul Deodhar 3, Corinne Miceli-Richard 4, Peter Nash 5, Naveed Sattar 6, Nehal Mehta 7, Darren Asquith 8, Jianyuan Wang 9, Hanno Richards 9, Luminita Pricop 10 and Abhijit Shete 9, 1Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 3Oregon Health & Science University, Portland, OR, 4Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 5University of Queensland, Brisbane, Queensland, Australia, 6Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, 7National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, 8Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, 9Novartis Pharma AG, Basel, Switzerland, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment…
  • Abstract Number: 1523 • 2019 ACR/ARP Annual Meeting

    Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis

    Alan Menter 1, Zoe Draelos 2, Jayme Heim 3, Jeff Parno 4, Alan Mendelsohn4, Stephen Rozzo 4 and Christopher Griffiths 5, 1Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX, USA, Dallas, TX, 2Dermatology Consulting Services, High Point, NC, USA, High Point, NC, 3West Michigan Dermatology, Holland, MI, USA, Holland, MI, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 5Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom

    Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody approved for the treatment of moderate-to-severe chronic plaque psoriasis. An inverse efficacy–body weight relationship has been…
  • Abstract Number: 1524 • 2019 ACR/ARP Annual Meeting

    Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study

    Alice Gottlieb 1, Ana-Maria Orbai 2, Rocco Ballerini 3, Richard C. Chou 4, Stephen Rozzo 3, Alan Mendelsohn3 and Luis R. Espinoza 5, 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 4University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, 5Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA

    Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved by the FDA to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo-controlled, phase 2b…
  • Abstract Number: 1525 • 2019 ACR/ARP Annual Meeting

    Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial

    Christopher Ritchlin 1, Vibeke Strand 2, Rocco Ballerini 3, Richard C. Chou 4, Stephen Rozzo 3, Alan Mendelsohn3 and Arthur Kavanaugh 5, 1Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, 2Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, Palo Alto, CA, 3Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 4University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, 5University of California, San Diego School of Medicine, La Jolla, CA

    Background/Purpose: Tildrakizumab (TIL) is an anti–interleukin-23p19 monoclonal antibody approved by the FDA for treatment of moderate-to-severe plaque psoriasis1,2 and is under investigation for treatment of…
  • Abstract Number: 1526 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study

    Wendy Cantrell 1, Patricia Lee 2, Emil Tanghetti 3, Alan Mendelsohn4, Jeff Parno 4, Stephen Rozzo 4 and Wilson Liao 5, 1Department of Dermatology, University of Alabama Birmingham, Birmingham, AL, USA; Dermatology at the Whitaker Clinic, Birmingham, AL, USA, Birmingham, AL, 2Center for Clinical Studies, Webster, TX, USA, Webster, TX, 3Center for Dermatology and Laser Surgery, Sacramento, CA, USA, Sacramento, CA, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 5Department of Dermatology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA

    Background/Purpose: We assessed residual plaque psoriasis in patients successfully treated with anti–interleukin-23p19 monoclonal antibody tildrakizumab (TIL) who interrupted treatment, relapsed, and were retreated vs continuously…
  • Abstract Number: 1527 • 2019 ACR/ARP Annual Meeting

    Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program

    Holly Glover 1, Kristine Kucera 2, Alan Mendelsohn3, Jeff Parno 3, Stephen Rozzo 3, Frank Ferritto 4 and Renata Block 5, 1Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA, McKinney, TX, 2North Texas Dermatology, Richardson, TX, USA, Richardson, TX, 3Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 4Polley Dermatology, Wilson, NC, USA, Wilson, NC, 5Pinski Dermatology & Cosmetic Surgery, Chicago, IL, USA, Chicago, IL

    Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody with demonstrated efficacy for the treatment of chronic plaque psoriasis in a phase 2b (P05495 [NCT01225731])…
  • Abstract Number: 1554 • 2019 ACR/ARP Annual Meeting

    Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study

    Philip Mease1, Robert B.M. Landewé 2, Proton Rahman 3, Hasan Tahir 4, Atul Singhal 5, Elke Böttcher 6, Sandra Navarra 7, Aimee Readie 8, Shephard Mpofu 9, Evie Maria Delicha 9, Luminita Pricop 8 and Désirée van der Heijde 10, 1Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 2Amsterdam University Medical Center, Amsterdam, Netherlands, 3Memorial University, Newfoundland, NL, Canada, 4Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, 5Southwest Rheumatology, Dallas, TX, 6Rheumazentrum Favoriten, Vienna, Austria, 7University of Santo Tomas Hospital, Manila, Philippines, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Novartis Pharma AG, Basel, Switzerland, 10Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Secukinumab (SEC) provided sustained efficacy, inhibition of radiographic progression, and stable safety profile over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA)…
  • Abstract Number: 1768 • 2019 ACR/ARP Annual Meeting

    A First-in-class Selective and Potent IRAK4 Degrader Demonstrates Robust in Vitro and in Vivo Inhibition of TLR/IL-1R Activation and Inflammation

    Veronica Campbell1, Joseph Kelleher 1, Jesse Chen 1, Jared Gollob 2, Nan Ji 2, Christine Klaus 2, Christine Loh 2, Michelle mayo 2, Alice McDonald 2, Haojing Rong 2, Scott Rusin 2, Kirti Sharma 2, Matt Weiss 2, Karen Yuan 2, Duncan Walker 2, Xiaozhang Zheng 2, Anthony Slavin 2 and Nello Mainolfi 2, 1Kymera Therapeutics, cambridge, MA, 2Kymera Therapeutics, Cambridge

    Background/Purpose: IL-1R/TLR activation plays a central role in the pathophysiology of multiple autoimmune and inflammatory diseases driven by the IL-1 family of cytokines and by…
  • Abstract Number: 1776 • 2019 ACR/ARP Annual Meeting

    Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study

    Dongze WU1, Priscilla Wong 1, Steven H.M. Lam 1, Isaac T. Cheng 1, Edmund K. Li 1, Ling Qin 1 and Lai-Shan Tam 1, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Biologic agents targeting cytokines including TNF-α, IL-12p70 and IL-17 have been proven to be very effective in treating psoriatic arthritis (PsA).  Nonetheless, whether these…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology